MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Mirum Pharmaceuticals, Inc. - common stock (NQ:MIRM)

68.48 -3.05 (-4.26%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 5, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Mirum Pharmaceuticals, Inc. - common stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
News headline image
Mirum Pharmaceuticals to Showcase Data from its LIVMARLI and Volixibat Clinical Programs at AASLD’s The Liver Meeting
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
Breaking Down Mirum Pharmaceuticals: 5 Analysts Share Their Views ↗
 
Via Benzinga
News headline image
Mirum Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
Earnings Scheduled For November 12, 2024 ↗
 
Via Benzinga
News headline image
Earnings Outlook For Mirum Pharmaceuticals ↗
 
Via Benzinga
News headline image
We Tested Top Stocks; Here’s What’s Best For Your Money ↗
Discover the top-performing stocks with our analysis. In this video, we dive into the Bollinger Band Squeeze strategy while scanning for opportunities. 
Via Talk Markets
News headline image
Analyst Expectations For Mirum Pharmaceuticals's Future ↗
 
Via Benzinga
News headline image
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
Mirum Pharmaceuticals to Announce Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
Mirum Pharmaceuticals to Showcase LIVMARLI Data from its ALGS and PFIC Programs at the NASPGHAN Annual Meeting
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
Volixibat Granted Breakthrough Therapy Designation for Cholestatic Pruritus in Primary Biliary Cholangitis
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
MIRM Stock Earnings: Mirum Pharmaceuticals Misses EPS, Beats Revenue for Q2 2024 ↗
MIRM stock results show that Mirum Pharmaceuticals missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024. 
Via InvestorPlace
News headline image
Mirum Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
Mirum Pharmaceuticals to Announce Second Quarter 2024 Financial Results and Host Conference Call on August 7, 2024
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
Mirum’s LIVMARLI Now Approved for PFIC in Patients 12 Months and Older
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
Mirum Pharmaceuticals’ LIVMARLI Approved in the European Union for Patients with PFIC
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
Mirum Submits New Drug Application to FDA for Chenodiol for the Treatment of CTX
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
Nvidia To Rally Around 53%? Here Are 10 Top Analyst Forecasts For Tuesday ↗
 
Via Benzinga
News headline image
Why Ovid Therapeutics Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
News headline image
Mirum Pharmaceuticals Highlights Encouraging Data For Rare Liver Disease Therapy From Two Mid-Stage Studies ↗
Mirum Pharmaceuticals announced promising interim results from Phase 2b studies of volixibat for primary biliary cholangitis and primary sclerosing cholangitis. Significant improvements in pruritus and... 
Via Benzinga
News headline image
Aaron's, Nvidia, Mirum Pharmaceuticals, Primo Water And Other Big Stocks Moving Higher On Monday ↗
 
Via Benzinga
News headline image
Mirum’s Volixibat Achieves Positive Interim Analyses in VANTAGE PBC and VISTAS PSC Studies
From Mirum Pharmaceuticals, Inc.
Via Business Wire
News headline image
Mirum Pharmaceuticals to Host Investor Call to Share Interim Analysis Results from the Volixibat VANTAGE and VISTAS studies on June 17, 2024
From Mirum Pharmaceuticals, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story